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Abstract: 
Most common SNPs are popularly assumed to be neutral.  We here developed novel methods to 
examine in animal models and humans whether extreme amount of minor alleles (MAs) carried 
by an individual may represent extreme trait values and common diseases.  We analyzed panels 
of genetic reference populations and identified the MAs in each panel and the MA content (MAC) 
that each strain carried.  We also analyzed 21 published GWAS datasets of human diseases and 
identified the MAC of each case or control.  MAC was nearly linearly linked to quantitative 
variations in numerous traits in model organisms, including life span, tumor susceptibility, 
learning and memory, sensitivity to alcohol and anti-psychotic drugs, and two correlated traits 
poor reproductive fitness and strong immunity.  Similarly, in Europeans or European Americans, 
enrichment of MAs of fast but not slow evolutionary rate was linked to autoimmune and 
numerous other diseases, including type 2 diabetes, Parkinson’s disease, psychiatric disorders, 
alcohol and cocaine addictions, cancer, and less life span.  Therefore, both high and low MAC 
correlated with extreme values in many traits, indicating stabilizing selection on most MAs.  The 
methods here are broadly applicable and may help solve the missing heritability problem in 
complex traits/diseases. 
 
Abbreviations:  
MAF: minor allele frequency 
MAC: minor allele content.   
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Introduction: 
Although past studies of complex traits/diseases have met with great success in identifying 
a number of significant genetic variants in various traits and diseases, such variants usually 
account for only a small fraction of the total trait variation and their functional roles typically 
remain unclear, which has led to the missing heritability problem (Burton, et al., 2007; Conrad, 
et al., 2010; Manolio, et al., 2009; O'Donovan, et al., 2008; Purcell, et al., 2009; Shi, et al., 2009; 
Stefansson, et al., 2009; Teslovich, et al., 2010).  The focus on searching for a few major effect 
variants is under the null hypothesis in the field of population genetics that the majority of 
genetic variations are neutral and hence irrelevant to phenotypes.  Notably, however, while the 
assumption of neutrality for most variations has often passed tests by sequence-alignment based 
informatics approaches, such methods usually have their own set of uncertain assumptions, 
including assuming certain DNAs to be neutral such as synonymous sites and transposon-
element derived sequences, and are therefore not truly conclusive tests free of neutral or 
uncertain assumptions (Fay, et al., 2002; Ponting and Hardison, 2011).  In contrast, direct tests 
by experimental science suggest at least 80% functional human genome (Dunham, et al., 2012). 
 While too little genetic variations are known to hurt adaptive capacities, it is much less 
appreciated whether too much may exceed an organism’s maximum level of tolerable entropy, 
given that mutations are after all random and disorderly in origin.  We here developed two novel 
methods to test whether the total amount of SNPs carried by an individual are under stabilizing 
selection.  First, we made use of multiple panels of genetic reference populations or recombinant 
inbred lines (RILs) that provide a powerful means to study the genetic basis of complex 
phenotypes (Ayroles, et al., 2009; Brem, et al., 2002; Perlstein, et al., 2007; Philip, et al., 2010; 
Philip, et al., 2011; Seidel, et al., 2008; Taylor, 1978; Vinuela, et al., 2010).  The RIL panels are 
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derived from breeding of parental strains differing in phenotypes and genotypes.  The F1 and F2 
or up to F10 progenies are intercrossed to maximize random recombination and hence allelic 
diversity in the offspring, which were then randomly selected for inbreeding up to 20 generations 
to generate the final panel of RILs homozygous for almost all variants or SNPs.  During the 
random mating and subsequent inbreeding process, there are ample opportunities for neutral 
variants to drift and for non-neutral variants to be positively and negatively selected.  Immunity 
against pathogens is essential for survival and depends on allelic diversity, which would 
positively select for enrichment of variants.  On the other hand, individuals may die or be aborted 
before birth due to abnormal development caused by enrichment of deleterious variants.  While 
the population size of a RIL panel is small, which favors neutral drift, the actual size of the 
offspring population of the original parents is much greater and includes many that died because 
of poor immunity or were never born due to en utero negative selection.   
If a trait is determined by multiple loci and robust to minor perturbations, one may expect 
that the trait may be genetically affected in two mutually non-exclusive ways.  One is a major 
effect mutation in one of these loci that alters a component of a multi-component pathway.  
Alternatively, it may take a large amount of minor effect mutations in multiple loci to harm the 
trait, while such mutations individually or even a small collection of them may have few 
discernable effects or even beneficial effects.  Furthermore, the variation in the number of such 
minor effect mutations may account for any quantitative variation in a trait, which characterizes 
most complex traits.  For example, the more the variants the better the immunity upto a point 
when too much variants may start to hurt other traits or be cancer prone. 
For any given panel of RILs, most SNPs would show MAs that are carried by less than 
half of the strains in the panel and the strains would differ in the contents of MAs that each 
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carries.  We defined “MA contents (MAC)” as the number of MAs in an individual divided by 
the number of SNPs scanned.   Different from MAF, MAC is an individual measure.   One 
predicts that strains with higher MAC should be similar to those with lower if the neutrality 
assumption is true.  Alternatively, they should show poorer measurements in certain adaptive 
traits while better in certain others that are known to depend on allelic diversity if the natural 
selection model is true.  We here tested these predictions by performing new trait analysis 
experiments as well as by using the large collection of data accumulated in the past several 
decades for genetic reference populations.   
Taking advantage of published SNP datasets from genome wide association studies 
(GWAS) of numerous human diseases that were typically genotyped at ~450-900K common 
SNPs, our second approach was to determine whether the MAC of a patient is different from that 
of a control.  We focused on diseases for which results in model organisms can provide 
independent evidence.   
 
Results: 
MA distribution profiles in genetic reference populations 
We calculated MAF for each scanned SNP in a panel of genetic reference population.  We 
then calculated MAC for each strain of a panel and plotted the MAC distribution curve (Figure 1 
and Supp. Table S1 for strain descriptions).  Great variations in MAC (~0.2 to ~0.7) were 
observed for C. elegans RILs from either the Kruglyak or the Kammenga laboratory (Figure 1A 
and B) (Seidel, et al., 2008; Vinuela, et al., 2010), the yeast segregant panel (Figure 1C) (Brem, 
et al., 2002; Perlstein, et al., 2007), and the BXD mouse RIL panel (Figure 1F) (Philip, et al., 
2010; Taylor, 1978).  Relative to these RILs, D. melanogaster inbred panel derived from the 
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wild showed lower MAC and smaller variation range (Figure 1D) (Ayroles, et al., 2009).  RILs 
that were only partially inbred such as the Collaborative Cross (CC) G2F7 mouse panel that has 
been inbred for only 7 generations also showed small variation range in MAC (Figure 1E) 
(Philip, et al., 2011).  For certain panels with large variations, an abrupt turn at the ends of the 
distribution curve, especially the higher end, was apparent, indicating an under-representation 
and hence lower survival success of strains with low or high MAC (Figure 1A-D, F).  The 
population distribution of MAC showed a bell curve as expected (Supp. Figure S1).  For 
calculating MAC, the number of informative SNPs used for each panel ranged from ~0.12K to 
~151K.  Since the SNPs are a random sampling of the genome, the number of SNPs used should 
not significantly affect the calculation of MAC.  Indeed as shown for the BXD mouse panel, 
MAC calculated from ~51K SNPs were highly similar to those calculated using two different 
non-overlapping sets of 1K SNPs randomly selected from the ~51K (Supp. Figure S2). 
 
MAC correlates with quantitative variations in complex traits in model organisms  
To determine whether MAC may affect reproductive fitness, we examined brood size of 42 
C. elegans RILs from the Kruglyak laboratory with Hawaii (HW) npr-1 genotype and 62 RILs 
with N2 npr-1 genotype (Figure 2A-B).  Their parental strains Hawaii CB4856 and Bristol N2 
differ in npr-1 by one major effect SNP (F215V).  Higher MAC was linked with lower brood 
size in a nearly linear fashion, with its effect stronger in HW npr-1 background (Figure 2A-B).  
The deleterious effect of higher MAC on reproductive traits was confirmed in three other RIL 
panels in mouse and rat, BXD, CC(G2F6), and BXHHXB (Supp. Table S2).  In addition, higher 
MAC was linked with lower life span in C. elegans and mouse (Supp. Table S2), less startle 
response in D. melanogaster (for males, Spearman r = - 0.23, p = 0.004) (Ayroles, et al., 2009), 
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and more chill coma response in D. melanogaster (for females, Spearman r = 0.22, p = 0.007) 
(Ayroles, et al., 2009). 
There are 3664 traits for the BXD mouse panel of 89 strains characterized by numerous 
studies (some unpublished) with data archived at GeneNetwork (Taylor, et al., 1999; Wang, et al., 
2003).  For p < 0.0001 and 0% FDR as determined by 100 permutations, there were 15 traits 
linked with MAs by Pearson and 15 by Spearman analysis, and there were 297 traits with P<0.05 
and 60% FDR by Spearman analysis (Supp. Table S3).  A few examples of significant results 
include lower maximum threshold to ethanol induced ataxia (Figure 3A) and lower blood ethanol 
concentration in males 20 min after ethanol injection (Figure 3B).  A number of related 
neurological traits were linked with higher MAC, including smaller methamphetamine-induced 
body temperature change, slower reversal learning, higher sensitivity to pain, less open field 
rearing behavior, more anxiety as assayed by the light-dark box method, less anxiety as assayed 
by the elevated plus maze assay, more depression as assayed by duration of immobility in a tail 
suspension test, more saccharin preference, and some cocaine related traits (Supp. Table S3 and 
S4).  However, MAC was not linked with morphine-induced difference in locomotion.  Other 
traits more definitively linked with higher MAC  (p < 0.0001 and 0 FDR) include higher adrenal 
weight, higher deoxycorticosterone level in cerebral cortex, and less value in the unpublished 
traits 274 and 372 of the AUW-BXD series that were significantly correlated with slower 
reversal learning (Supp. Table S3).   
Most of the 3664 traits in Supp. Table S3 were scored for less than half of the panel and 
different sets of strains were often used for scoring different traits.  After filtering out traits and 
strains with too many missing data, we were able to perform multivariate regression analysis on 
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9 traits, which identified 3 significant associations, including blood ethanol concentration, 
adrenal zona fasciculata width, and hair coat color (Supp. Table S5).   
A number of traits were repeatedly found linked with MAC in different panels of RILs 
(Supp. Table S2).  One was tumor susceptibility (Figure 4 and Supp. Table S2).  The effect of 
MAC in urethane induced lung tumor was only apparent when kras2 oncogene was wild type 
(Figure 4A vs 4B)(Ryan, et al., 1987).  There were also traits such as blood pressure that were 
repeatedly not found associated with MAC (Supp. Table S2).   
MAC also consistently associated with traits linked to obesity, type 2 diabetes (T2D) and 
Parkinson’s disease (PD).  In BXHHXB rat, more MAs were linked with higher glucose level 
after high fructose diet (Figure 5A) and lower serum dopamine level (Figure 5B).  In high fat diet 
fed BXD mice, higher MAC correlated with traits associated with obesity and T2D, including 
higher resistin level and more body weight increase, increased food intake, higher oxygen 
consumption, and lower transferring saturation (Supp. Table S3 and S4).   
The expectation of a link between immunity and allelic diversity was confirmed in two 
panels of mouse RILs (BXD and BXH) with higher MAC associated with stronger immunity 
(Table 1).   
For the yeast segregant panel, we analyzed the published 316 response profiles to 92 drugs 
and chemical compounds including 18 Food and Drug Administration (FDA)-approved drugs 
(Perlstein, et al., 2007).  By SAM analysis, we identified 12 traits at 0 FDR among 316 drug 
response traits.  All 12 traits showed more growth inhibition in strains with higher MAC, 
suggesting less reproductive abilities of these segregants under certain environmental conditions 
but never more under any of the 316 conditions examined here.  Seven among these involved 4 
drugs that are FDA-approved antipsychotic and antidepression drugs (sertraline, trimeprazine, 
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chlorpromazine, and trifluoperazine), and one involved the FDA-approved breast cancer drug 
Tamoxifen (Supp. Table S6).  The remaining four traits involved three chemical compounds and 
there was an enrichment of FDA-approved drugs among chemical compounds with effects on 
strains with higher MAC (5 of 18 vs 3 of 74, p < 0.01, chi-square test).     
 
Trait specific set of MAs  
While many different traits were linked with MAC, most of them did not share the same 
set of MAs since a trait was only correlated with some but not most other traits (Supp. Table S4).  
For example, blood ethanol concentration (BEC) strongly correlated with resistin level but not 
pain response and open field rearing behavior (Supp. Table S4).  To confirm among the MAC-
linked traits that correlated traits share more MAs than non-correlated traits, we developed an 
approach to identify trait specific set of MAs as described in the Methods.  From 51469 SNPs 
originally used for calculating MAC for the BXD panel, we identified a BEC-specific set of 
30336 SNPs.  When the MAC value was calculated using the BEC specific set, the BEC trait 
was strongly linked with MAC (Spearman r = - 0.66, p = 0.0004) and so was its related trait 
resistin level (r = 0.53, p = 0.008).  No strong association was noted for its two non-related traits, 
rearing behavior (r = - 0.4, p = 0.06) and pain (r = - 0.46, p = 0.03), thus demonstrating the 
specificity of the BEC-specific set of SNPs.  In contrast, using the non-trait specific set of 51469 
SNPs, two non-related traits, resistin level and pain response, scored the best correlation with 
MAC.   
We next examined whether poor reproductive fitness and strong immunity are correlated 
traits.   The MAC-linked reproductive trait in BXD mice is uterus horn length at maturity as 
shown in Supp. Table S2.  There was a correlation between this trait and formation of secondary 
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dermal lesions upon Ectromelia virus infection of footpad (Pearson r = 0.40, p = 0.028 for mixed 
sexes).   Such correlation suggests sharing of SNPs in reproduction and immunity. 
 
MAC in common diseases 
The above results in model organisms suggest that higher MAC may contribute to certain 
human diseases.  We made use of published GWAS datasets of Europeans or European 
Americans (EA), which generally have cases well matched with controls in terms of population 
straitification.  We identified the MAs of informative autosomal SNPs in the control population 
of each study and determined the average distance of either cases or controls to the set of MAs.  
Smaller distance to the MA set means greater MAC.  For most of the diseases here, we studied at 
least two independent datasets in order to verify a positive link.  
As shown in Table 2, all diseases studied except hypertension and coronary artery disease 
(the former is a high risk factor for the latter) consistently showed higher MAC in cases (most 
with p < 0.01).  Higher MAC correlated more often with higher heterozygosity and greater 
pairwise genetic distance, as may be expected (Table 2).  While we only had one dataset for each 
of the three autoimmune diseases studied here, type 1 diabetes, inflammatory bowel disease, and 
rheumatoid arthritis, the fact that all three showed linkage with higher MAC indicates a 
consistent pattern for autoimmune disease as a whole.  In all diseases with higher MAC in cases, 
there was at least one cohort showing significant Spearman correlation between higher MAC and 
cases (r > 0.036, p < 0.05), where we mixed cases and controls with case status as 1 and control 
as 0 and tested how well the MAC of each subject correlated with case status.  The strongest 
correlation was found in one PD cohort (Spearman r = 0.21, p < 0.0001) and the weakest for 
rheumatoid arthritis (Table 2).   We then picked the Wellcome Trust Case Control Consortium 
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(WTCCC) T2D dataset as an example to see how the MAC linkage with case status compares to 
top SNP hits previously identified by GWAS that typically have trend p < 5 x 10-7 (Burton, et al., 
2007).  The Spearman correlation between MAC and case status in WTCCC T2D (r = 0.085, p < 
0.0001) was similar to that between genotype and case status for the top T2D-associated SNP 
rs4506565 with reported trend p = 5.68 x 10-13 (r = 0.105, p < 0.0001) and rs9939609 with trend 
p = 5.24 x 10-8 (r = 0.076, p = 0.0001) (Burton, et al., 2007).  As a further control, two randomly 
chosen control populations from PD data showed no significant difference in MAC.     
Although the GWAS datasets have controlled for population stratification, we used a novel 
strategy to confirm it.  Slow evolving sequences are more likely to follow the infinite sites model 
of the neutral theory while fast evolving ones are likely to have reached saturation where new 
mutations would occur at old sites that have encountered mutations before.  Therefore, one 
should observe a dramatic difference between SNPs of fast and slow evolutionary rates if indeed 
time has been long enough for most fast evolving SNPs to reach saturation.  As shown in Table 2, 
non-synonymous SNPs located in the slowest evolving proteins showed higher MAC in controls 
relative to cases in 12 of 21 datasets with two being significant (dbGaP T2D female and male 
cohorts, Table 2).  The other 9 datasets showed higher MAC in cases also with two being 
significant (dbGaP major depression cohort 2 and lung cancer H610).  The nearly even split of 
the datasets into those with higher MAC in controls versus those in cases was to be expected if 
the cases and controls were well matched.  Thus, the higher MAC in 19 of the 21 sets of cases as 
measured by most common SNPs, which mostly locate in relatively fast evolving sequences, is 
not due to population stratification (difference between slow and fast SNPs was significant: 19 of 
21 vs 9 of 21, p < 0.01, chi-square test).  Also, if MAs in fast evolving sequences have no roles 
in human diseases in general, we should not expect a significant excess of datasets with higher 
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MAC in cases (19 of 21, p < 0.01, chi-square test).  Indeed, results with slow SNPs showed the 
expected equal distribution of MAs in cases and controls (9 datasets with higher MAC in cases 
vs 11 with higher MAC in controls, p > 0.05, chi-square test).   
This difference between slow and fast SNPs was not due to the trivial reason that the 
number of slow SNPs analyzed was much smaller than that of fast SNPs, because randomly 
selected sets of small number of fast SNPs gave similar results as the large sets of fast SNPs.  For 
example, for PD cohort1, three randomly selected non-overlapping sets of 168 fast SNPs all 
showed significantly more MAs in cases with p < 2.0E-4, whereas in contrast the same number 
of slow SNPs showed insignificantly higher MAC in controls as shown in Table 2.   
Finally, we examined MAC relationship with clinical traits in cases and controls where 
such information was available.  Among alcohol addiction cases, MAC correlated with 7 traits of 
cocaine addiction but not with marijuana and opiate addictions (Supp. Table S7).  In both cases 
and controls in the alcohol addiction study, higher MAC was linked with lower education grade 
level achieved, consistent with its role in slower learning and memory as above found for mice.  
The PD dataset has age of death information for some of the control subjects and revealed a link 
between more MAC and shorter life span.  The PD control dataset also showed a link between 
more MAC and higher intake of over the counter non-steroid anti-inflammatory drugs (NSAIDs), 
confirming the link between MAC and over-active immune system as above observed for 
autoimmune diseases.   
 
Discussion: 
Our results show a connection between MA contents and numerous traits and diseases.   
MAC was linked with poorer rather than better performance in many adaptive traits.  Lower 
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reproductive fitness such as smaller uterus may be sufficient to explain the lower frequency of 
some of these MAs.  Negative selection en utero may also do so, and the deleterious effects of 
these MAs on some adult traits/diseases may reflect pleiotropy.  Thus, the minor nature of MAs 
linked with late onset diseases such as T2D and PD may reflect negative selection en utero rather 
than by these diseases per se.   In contrast, the link between higher MAC and better immunity 
and the inverse correlation between immunity and reproduction indicate simultaneous positive 
selection of the negatively selected MAs and explain why a common MA should be common 
rather than rare.    
 Immunity and reproduction may not be the only traits to make possible both positive and 
negative selection of an MA.  A more general way is the negative selection of extreme MAC 
associated with extreme measurements of numerous quantitative traits (Figure 6).  The adaptive 
advantages of allelic diversity are well appreciated by past studies, including conferring a wide 
range of quantitative variations in nearly all complex traits.  For most quantitative traits, the two 
extremes of trait measurements, either high or low, represent suboptimum population minorities, 
and are negatively selected by way of ultimately affecting reproductive fitness as most traits 
could be somehow related to reproduction given its central role in evolution.  The two extremes 
would be represented by high and low MAC if the quantitative variations in such traits are 
related to the additive effect of MAs as shown here for numerous traits as well as by the 
observation that traits known to have large number of additive QTLs are more likely to be 
affected by MAC (Zhu, et al., 2013).  Thus both high and low MAC would be negatively 
selected, which means both positive and negative selection for these MAs.  For example, too 
weak or too strong immunity would be both negatively selected.  The same goes for too low or 
too high anxiety (or depression, adrenal weight, deoxycorticosterone level, etc).  However, the 
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extreme value of a trait variation linked with low MAC should be less harmful than the other 
extreme linked with high MAC since after all these alleles are minor or on the whole slightly 
deleterious.  Thus, while diseases linked with low MAC are expected to exist (congenital 
immunodeficiency syndromes may be one), they may be less common.   
This study here analyzed more than 4000 traits for associations with MAC in animal 
models and humans.  Hundreds of associations passed the significance value of P < 0.05.   Most 
of these should be considered as results of an exploratory study needing future verification.  
Using a multiplicity adjustment method such as the Bonferronni correction here would eliminate 
most of these associations as insignificant false positives but the correction is widely known to 
have a few fallacies to deem its use here improper (Perneger, 1998)    In addition to defying 
common sense, the Bonferronni correction increases type 2 errors or the chance of false 
negatives especially when involving extremely large number of tests as was the case here.  
Typical GWAS studies  do make multiple test corrections based on uncertain assumptions and 
cannot draw meaningful conclusions on SNPs with P values between 0.05 and 5 x 10-7  (Burton, 
et al., 2007).  But as shown here by the MAC concept/methods, most such SNPs may in fact be 
significant.  Most animal experiments have small sample sizes due to practical and financial 
reasons.  The value of our study is to give the community a select list of MAC-linked traits 
worthy of future confirmatory studies.   A future study testing one of the linked traits here would 
only have one hypothesis to test and thus only need to achieve standard P value ( <0.05).     
Do the results here mean an additive effect of large numbers of MAs in MAC action and 
hence non-neutrality of most MAs?  Many major effect risk alleles of diseases are known to be 
minor alleles (Park, et al., 2011), which may plausibly imply that the effect of MAC may be 
mediated by a few known major effect risk alleles rather than large numbers of minor effect MAs.  
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But this may not be the case.  The effect of MAC was in fact abolished or weakened by major 
effect MAs such as kras2 mutation in lung cancer or npr-1 mutation in brood size.  Furthermore, 
MAC preferentially affects traits with larger number of known additive QTLs (Zhu, et al., 2013).  
It is self-evident that the more the number of QTLs involved in a trait, the less the individual 
effect of each QTL on the trait.  These results also mean that the effect of MAC would become 
much more obvious and significant after filtering out individuals with major effect MAs such as 
kras2 or npr-1 mutation, which is exactly the opposite of what one would predict from the notion 
of MAC involving known major effect MAs.  Thus, MAC-linked diseases are expected to have 
more additive minor effect SNPs as risk alleles than those not linked to MAC.   The individual 
effect of such SNPs may not be possible for existing methods like GWAS to detect.  In this sense, 
the concept and methods of MAC here may help solve the “missing heritability” problem of 
some complex diseases/traits.  Major effect risk alleles and MAC may each account for different 
fractions of a case population.   The size of the fraction accounted by MAC needs to be 
determined by future studies using trait/disease specific set of MAs and filtering out cases linked 
with major effect MAs.  We predict further that cases associated with major effect risk alleles 
should have different defects and hence be treated differently from those linked with MAC. 
The results here in model organisms and humans suggest that most common MAs in any 
species are nearly neutral or slightly deleterious resulting from both positive and negative 
selection.  As new mutations constantly introduce more MAs, a slightly more dominant negative 
selection relative to positive selection is absolutely necessary in order to prevent allelic diversity 
to be over an optimum limit.  In contrast, positive selection may not always be necessary for 
MAs to reach an optimum amount as mutations plus time or neutral drift can do so too if only 
slowly.  At the optimum level of allelic diversity, the overall slightly deleterious nature of MAs 
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would be in homeostasis with the slightly beneficial nature of major alleles.  The optimum 
concept here means a Pareto optimum or simply the best that can be achieved due to a balance 
between positive and negative selection at a particular time point under a specific level of 
epigenetic or organismal complexity (Shoval, et al., 2012).  As time and complexity changes, the 
optimum level of nucleotide diversity will also change.  While what determines genetic diversity 
has been a long-standing unsolved puzzle (Leffler, et al., 2012), the results here suggest a critical 
role of the internal system construction requirements of the species or its level of complexity. 
The results here that cases have more MAC or nucleotide diversity provides further direct 
evidence for the inverse relationship between genetic diversity and epigenetic complexity and the 
Maximum Genetic Diversity (MGD) hypothesis, a more complete account of evolutionary and 
hereditary phenomena that views most random mutations as entropy generating rather than 
neutral (Hu, et al., 2013; Huang, 2008; Huang, 2009; Huang, 2010; Huang, 2012).   The MGD 
absorbs all the proven virtues of the neutral theory and natural selection in describing the linear 
phase of evolution where genetic distance is linearly related to time, but considers most sequence 
divergence observed today are in fact at optimum or maximum levels.  Certain key evidence of 
maximum divergence,  such as the genetic equidistance result of Margoliash,  has been 
unfortunately misinterpretated by the neutral perspective for nearly half of a century (Hu, et al., 
2013; Huang, 2008; Huang, 2009; Huang, 2010; Huang, 2012; Margoliash, 1963).   A useful 
standard for judging the validity of a theory about the past may be to see how relevant it is to 
solving problems of today, since knowing the past should help know the present.  The studies 
here were inspired by the MGD hypothesis and illustrate its practical value to contemporary 
problems.  In contrast, by assuming ~90% of the human genome as junks or neutral (Ponting and 
Hardison, 2011), the neutral theory has self rendered itself irrelevant to the information/traits 
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associated with such DNAs and not unexpectedly cannot help with, if not in fact creating, the 
missing heritability problem.   
Ohta’s theory of slightly deleterious or nearly neutral mutations works nearly as well as 
Kimura’s neutral theory in explaining the behavior of genetic polymorphisms (Ohta, 1973).  But, 
a serious problem with it from the perspective of the existing framework as pointed out by Nei 
and Kumar (Nei and Kumar, 2000) is that “if slightly deleterious mutations are abundant and are 
fixed in the populations continuously, the genes will gradually deteriorate and eventually lose 
their original function.”  The results here show that these mutations cannot accumulate without a 
limit and are negatively selected in bulk, as predicted by the MGD.   However, the nearly neutral 
theory predicts no such limit on genetic diversity, and is hence disproven by the results here.   
Similar to the laws in hard sciences such as physics and mathematics for which the 
foundations are intuitions or axioms, both Darwin’s natural selection and Kimura’s neutral 
theory, as applied in population genetics for sequences yet to reach optimum diversity, are also 
self-evidently true or could be viewed as a deduction of an intuition in construction that random 
errors/noises within tolerable levels can be neutral, deleterious, or beneficial depending on 
circumstances.  Limited genetic diversity at optimum level are more likely to be beneficial than 
deleterious because they are within tolerable levels and confer strongest possible adaptive 
capacity to environmental challenges.  The benefit to immunity as shown here confirms the 
adaptive value of allelic diversity key to Darwin’s theory.  The absence of a link between 
diseases and MAs of slow evolutionary rate confirms the proven virtues of the neutral framework 
as applied to neutral sequences yet to reach optimum diversity.  However, the existing 
framework fails to recognize another related intuition key to the MGD hypothesis that excess 
entropy/noises would be deleterious even though limited amount could be neutral or beneficial.   
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Most mutations are random and hence disorderly in origin (regardless whether the mutations 
may benefit a specific gene function), which can only be expected to be disruptive to the internal 
integrity of a system of great order.  Any positively selected beneficial mutation therefore must 
be also at some point under negative selection because as a disorderly error it would contribute to 
the accumulation of entropy.  This intuition is strongly supported by the data here.  The existing 
framework also considers any observed genetic variations to be nowhere near an optimum level 
if granting any such level at all.  It fails to see that if genetic variation in the form of limited 
amount of MAs is adaptive as in immunity, it would be quickly positively selected to reach a 
level where it cannot go beyond due to negative selection.    
The effects of excess MAC in humans, both yes (such as T2D) and no (blood pressure), are 
remarkably similar to those in model organisms, suggesting that the link between excess MAC 
and diseases in humans is causal since it can be independently replicated in model organisms.   
This is all the more remarkable as the MAs were identified differently and independently in 
humans and model organisms, indicating again that MA amounts matter more than the specific 
function of individual MA.  Also reassuring is that many MAC-linked traits were independently 
observed in different panels of RILs.  Taken together, these independent and mutually supportive 
results confirm the power and validity of the experimental approaches employed here. 
The results here suggest insights into the pathogenesis of certain diseases.  It is well 
established that accumulation of somatic mutations causes cancer, although most such mutations 
are assumed to be neutral or “passengers” rather than “drivers” (Vogelstein, et al., 2013; Wood, 
et al., 2007).  The results here that individuals with more germline SNPs or MAC have higher 
lung cancer incidences suggests an oncogenic role for most presumed neutral mutations and may 
explain the well-known variation in humans in lung cancer risk when exposed to the same 
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pathogenic factors such as cigarette smoking.  This makes good sense since cells with more 
random variations or SNPs should have more entropy, which would make growth control less 
precise and stable.  Alcohol addiction in humans is associated with lower initial sensitivity to 
alcohols/drugs and strong alcohol and sweet preference and consumption (Crabbe, 2002).  
Strains with high MAC showed these phenotypes and may thus serve as good models of human 
alcoholism, although more future studies are needed.  High MAC in mice were linked with 
increase in resistin and insulin level and decrease in IL-17 level.  Such alterations have been 
implicated in mouse and human obesity and T2D and may mediate in part the pathogenic 
pathways in T2D associated with MAs (Steppan, et al., 2001; Zuniga, et al., 2010).   If these 
biochemical changes could be confirmed by future studies, mice with high MAC may serve as 
useful models of obesity and T2D.  Also,  T2D patients are known to have higher risk of PD (Hu, 
et al., 2007), which is associated with loss of dopamine secreting neurons in the substantia nigra.  
Greater than half of PD patients exhibit abnormal glucose tolerance or diabetes (Boyd, et al., 
1971; Lipman, et al., 1974).   The finding of MAC association with both glucose and dopamine 
level, if confirmed by future studies, may help understand the common genetic mechanisms for 
T2D and PD.   
MAC may cause disease susceptibility by making inherent traits less stably maintained or 
inherited during cell division (Zhu, et al., 2013).  But the mechanism of action of MAC in 
complex diseases/traits may be hard to delineate precisely and usefully, since the defining 
characteristic of complexity may be the breakdown of causality.  As simply put by Goldenfeld 
and Woese, “complex systems are ones for which observed effects do not have uniquely 
definable causes, due to the huge nature of the phase space and the multiplicity of paths.”  
(Goldenfeld and Woese, 2011).   Thus, holistic system or architectural plan approaches may be 
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more productive in studying MAC action than old fashioned ways of focusing on individual  
building blocks or genes.    
The number of MAC-linked traits found in this analysis of ~4700 traits in genetic reference 
populations may be only a conservative minimum since most of these traits were only assayed in 
few strains, which cannot meet sampling size requirements for significant results.  Also, if the 
SNPs used for calculating MAC were not truly a random sampling of the genome, they could 
miss certain traits.  In the absence of complete SNP genotyping data representing all haplotypes, 
it may be premature to identify trait-specific set of MAs since such set is inherently incomplete.  
But even an incomplete set may still prove useful for certain practical purposes such as 
trait/disease risk predictions.   Future studies using the methods here or improved versions of 
them may uncover more MAC-associated traits and identify trait/disease specific set of MAs 
useful for diagnosis.      
 
Materials and methods: 
 
MAC calculation and statistical methods: 
Disease SNP GWAS datasets were downloaded from European Genome-phenome Archive 
(EGA) and database of Genotypes and Phenotypes (dbGaP).  Duplicated individual datasets were 
excluded from the analysis.  For certain large datasets such as PD and major depression, the data 
were randomly split into two cohorts to mimic two independent studies.  SNP data for the 
genetic reference populations were obtained from the literature and public databases.  All 
analyses were done with autosomal SNPs.  Phenotype and gene expression data were from the 
literature, GeneNetwork, and Gene Expression Omnibus.   
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The MAF of each SNP in a RIL panel or a control cohort was calculated by PLINK and 
SNP Tools for Microsoft Excel (Chen, et al., 2009; Purcell, et al., 2007).  The number of strains 
in each RIL panel is given in Supp. Table S1.   From such MAF data, we obtained the MA set, 
which excluded non-informative SNPs with MAF = 0 in both cases and controls or in a RIL 
panel and with MAF = 0.5 in controls or a RIL panel.  The MA set was equivalent to an 
imagined individual who is homozygous for all the MAs of informative SNPs analyzed.  
Three SNP parameters related to nucleotide diversity were scored using a novel software 
Nucleotide Diversity 1 (ND1) developed for this study, including distance to the MA set, Het 
number, and pairwise genetic distance (PGD).  Every non-repetitive pair within a population was 
scored to produce the average PGD.  The ND1 software measures genetic distance between two 
individuals by the number of mismatched SNPs.  For homozygous (Hom) vs Hom mismatch, a 
difference of 1 was scored.  For Hom vs Het, a difference of 0.5 was scored.  For Het vs Het, a 
difference of 0.5 was scored since half of such cases are expected to be A/B vs A/B with a 
difference of 0 whereas the other half are expected to be A/B vs B/A with a difference of 1.  We 
assumed that on a genome wide scale, the number of A/B vs A/B match due to IBD (identical by 
descent) is similar to the number of A/B vs B/A mismatch.  We verified this approach by 
comparing the PGD in X chromosome for CEU females vs CEU males using HapMap SNP data 
and found them to be similar as expected.  In contrast, a software based on IBS (identical by 
status) such as PEAS that scores Het vs Het as 0 showed the males to have much greater PGD in 
X than females (Xu, et al., 2010).  For the missing genotypes N/N, N/N vs Hom was scored as 0 
and N/N vs Het as 0.5.   
From the distance to the MA set which was the number of mismatched SNPs between an 
individual and the MA set, we obtained the amount of MAs each individual carries by 
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subtracting the distance from the total number of SNPs scanned.  The MAC of a strain was 
calculated by dividing the number of MAs carried by the strain by the number of total SNPs 
scanned.  The effect of non-informative N/N genotypes has been taken into account or corrected 
for calculating the MAC, as wells as for calculating the distance to the MA set and the number of 
Het.  For the distance to the MA set, the formula for N/N correction is: Corrected distance Y = 
Pre-correction distance + # N/N x (Y/# total SNPs). 
The correlation between genotype and phenotype was analyzed by linear and multivariate 
regression analysis using GraphPad Prism 5 and InStat3 and SAM.   For multivariate regression 
analysis of the 3664 traits in BXD panel, most traits were unsuitable for analysis because of 
missing data.  After removing these, there were 21 traits left, from which 13 were filtered out 
because of non-independent nature based on multivariate analysis.  The remaining 9 traits were 
then analyzed by multivariate regression using InStat3.  Other statistical methods used include 
Student’s t test, two tailed, chi-square test, two tailed, linear and multivariate regression, and 
Pearson/Spearman correlation analysis.   
 
Identification of trait specific set of MAs 
To confirm among the MA-linked traits that correlated traits share more MAs than non-
correlated traits, we examined four traits shown in Table S2, blood ethanol concentration (BEC, 
trait 3), its strongly correlated trait resistin level (trait 11), and its two non-correlated traits pain 
response (trait 4) and open field rearing behavior (trait 5), in order to identify a BEC specific set 
of SNPs or MAs.  From 51469 SNPs originally used for calculating MAC for the BXD panel, we 
identified 34709 SNPs using 61 strains with BEC data, with each SNP having more MAs in the 
bottom one third of the panel with the lowest BEC relative to the top one third with the highest 
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BEC.  We did this by converting each genotype of a SNP in a strain into a score of 0 for hom 
MA, 0.5 for het, and 1 for hom major allele.  These MAs were then ranked by p value from t test 
on their different enrichment in the bottom one third versus the top one third of the panel,  and 
divided into several groups, including groups with p <0.05, 0.05-0.11, 0.11-0.2, <0.2, 0.2-0.5, 
<0.5, 0.5-0.75, <0.75, 0.75-1, and 0-1.  We used each group of SNPs or MAs to calculate the 
MAC of each strain, which were then used to correlate with the 4 traits for a panel of 24 strains 
with each having data for all 4 traits.   The group of 30336 SNPs with P < 0.75 was found to 
have the best BEC specificity.   
 
Identification of non-synonymous SNPs located in the slowest evolving genes 
To obtain non-synonymous SNPs located in the slowest evolving genes, we collected the 
whole genome protein data of Homo sapiens (version 36.3) and Macaca mulatta (version 1) 
from the NCBI ftp site (ftp://ftp.ncbi.nih.gov/genomes/) and then compared the human protein to 
the monkey protein using local BLASTP program at a cut-off of 1E-10.  We only retained one 
human protein with multiple isoforms and chose the monkey protein with the most significant E-
value as the orthologous counterpart of each human protein.  The aligned proteins were ranked 
by percentage identities.  Proteins that show the highest identity between human and monkey 
were considered the slowest evolving (including 83 genes > 200 amino acid in length with 100% 
identity and 74 genes > 1105 amino acid in length with 99% identity between monkey and 
human), which additionally showed fewer number of coincident or overlapped substitutions than 
fast evolving genes among different lineages.  We downloaded the HapMap coding SNPs data 
from the dbSNP database (Build 130; ftp://ftp.ncbi.nih.gov/snp/), including the ancestral allele 
information, the gene locations of all SNPs and the allele frequencies of SNPs in four 
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populations CEU, CHB, JPT and YRI.  We thus obtained a list of 414 non-synonymous SNPs 
located in the slowest evolving proteins.   
 
Animal experiments: 
Ethics Statement: The study performed animal experiments and the animals’ care was in 
accordance with institutional guidelines.   The Institutional Animal Care and Use Committee of 
the Central South University has approved this study. 
For brood size measurement, all lines were synchronized by transferring five adult 
nematodes to fresh dishes and allowing them to lay eggs for 3-4 h, after which the nematodes 
were removed.  Twenty L4 individuals from each line were picked into 20 dishes and were 
allowed to lay eggs each day into a new dish for a total 8 days or until no more eggs were laid.  
The eggs in each dish were allowed to develop for 2 days before being counted. 
See Extended experimental procedures for experiments on immune responses and high fat 
diet-induced obesity in BXD mice.   
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Figure Legends: 
 
Figure 1.  Distribution profile of MAC of each strain in a panel of genetic reference 
population.  A.  RIL strains from the Kruglyak laboratory separated by the npr-1 F215V 
mutation into the HW and N2 types.  B. RIL strains from the Kammenga laboratory.  C.  
Budding yeast segregant panel.  D.  D. melanogaster inbred strain panel derived from randomly 
selected individuals in the wild.  E.  Mouse RIL panel from Collaborative Cross at 7th generation 
of inbreeding.  F.  Mouse BXD RIL panel.   
 
Figure 2.  MAC on reproductive fitness in C. elegans.  A.  Brood size in Kruglyak RIL strains 
with HW npr-1 genotype.  B.  Brood size in Kruglyak RIL strains with N2 npr-1 genotype.   
 
Figure 3.  MAC on ethanol traits in BXD mice.  A.  Maximum threshold to ethanol induced 
ataxia.  B.  Blood ethanol concentration in males.   
 
Figure 4.  MAC on tumorigenesis in mouse RILs.  A.  The number of lung tumors induced by 
urethane in kras2 wild type AXBBXA strains.  B.  The number of lung tumors induced by 
urethane in kras2 mutant AXBBXA strains.  Also shown are average tumor values of top and 
bottom half in MAC and t test p values.   
 
Figure 5.  MAC on obesity and PD related traits in rat RILs.  A.  Glucose concentration in 10 
week old BXHHXB male rats fed a diet with 60% fructose from 8 weeks to 10 weeks.  B.  
Serum dopamine level in 6 week old male BXHHXB rats.   
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Figure 6.  Purifying selection of both high and low MAC.    
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Table Legends: 
 
Table 1.  MAC on immune responses in mouse RIL panels. 
 
Table 2.  Distance to the MA set, heterozygosity, pairwise genetic distance (PGD), and 
correlation between MAC and case status.  a Shaded numbers indicate greater MA content or 
nucleotide diversity.  Numbers represent ratio of the distance to the MA set (or Het# or PGD) 
over the number of SNPs analyzed.  b t-test, p value, two tailed.  c ~0 means p < 2.2E-16.   
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 Table 1.  MAC on immune responses in mouse RIL panels     
Mice GN IDa 
Sample 
# 
Trait description Pearson Spearman 
                r p r p 
BXD 13969 24 CFU in liver 48h post i.v. S. aureus infection   -0.57 0.003 -0.66 0.0005 
  14313 6 White blood cell count after C. albicans IV infection   0.93 0.01 0.83 0.04 
  10779 18 IgG1 anti-cF.IX (coagul. Factor IX) after cF.IX injection   0.6 0.01 0.48 0.04 
  10695 21 Pulmonary granulomatous inflammation by BCG   -0.47 0.03 -0.39 ns 
  12668 33 Formation of dermal lesions, ECTV footpad   -0.36 0.04 -0.32 ns 
  10663 20 Cytotoxicity in spleen T cells post AdLacZ i.v injection   -0.43 ns -0.55 0.01 
  10806 25 Mortality after i.p. C. psittaci infection   -0.39 0.05 -0.43 0.03 
BXH 10115 10 Survival times of allograft   -0.68 0.02 -0.6 0.04 
aGeneNetwork identification number. 
           
 
 
Table 2.  Distance to the MA set, heterozygosity, pairwise genetic distance (PGD), and correlation between MAC and case status.   
 All types of SNPS Non-syn SNPs 
        Spearman   
Disease Dist. MA stdev Het stdev PGD stdev r p SNP # Dist. MA SNP# Sample # 
WTCCC T2D         
case 0.7958a 0.0083 0.2780 0.0095 0.2774 0.0089 0.09 <0.0001 485959 0.8288 23 1999 
control 0.7963 0.0022 0.2769 0.0035 0.2770 0.0024    0.8263  3004 
pb 0.008  2.0E-08  ~0c     ns   
dbGAP T2D European American (EA) female, phs000091.v2.p1 
case 0.7968 0.0041 0.2750 0.0031 0.2742 0.0025 0.05 0.002 830203 0.8815 49 1767 
control 0.7976 0.0047 0.2751 0.0035 0.2743 0.0033    0.8220  1537 
p 5.5E-08  ns  ~0     ~0   
dbGAP T2D EA male, phs000091.v2.p1 
case 0.7926 0.0047 0.2804 0.0037 0.2805 0.0033 ns  811523 0.8180 48 1115 
control 0.7928 0.0048 0.2803 0.0037 0.2804 0.0033    0.8154  1277 
p ns  ns  ~0     0.04   
dbGAP PD cohort1 EA, phs000196.v2.p1 
case  0.7855 0.0024 0.2899 0.0028 0.2903 0.0025 0.14 <0.0001 863755 0.8587 168 1000 
control 0.7859 0.0026 0.2898 0.0024 0.2905 0.0081    0.8576  999 
p 0.0006  ns  ~0     ns   
dbGAP PD cohort2 EA, phs000196.v2.p1 
case 0.7850 0.0017 0.29063 0.0029 0.2910 0.0018 ns  861405 0.8594 169 1011 
control 0.7854 0.0016 0.29064 0.0034 0.2908 0.0016    0.8596  993 
p 6.1E-05  ns  ~0     ns   
dbGAP PD H550,EA, phs000089.v3.p2 
case  0.7604 0.0044 0.3175 0.0065 0.3236 0.0032 0.21 <0.0001 544580 0.7754 84 672 
control 0.7611 0.0041 0.3194 0.0052 0.3233 0.0024    0.7746  527 
p 2.3E-05  7.2E-09  ~0     ns   
dbGAP Major depression cohort 1, phs000020.v2.p1 
case  0.7468 0.0086 0.3420 0.0054 0.3419 0.0038 0.13 <0.0001 450394 0.8336 109 1000 
control  0.7476 0.0059 0.3418 0.0037 0.3413 0.0023    0.8354  1000 
p 0.005  ns  ~0     ns   
dbGAP Major depression cohort 2, phs000020.v2.p1 
case  0.7470 0.0129 0.3419 0.0075 0.3414 0.0047 0.15 <0.0001 450338 0.8317 109 813 
control  0.7476 0.0064 0.3416 0.0041 0.3413 0.0028    0.8350  911 
p 0.006  ns  ~0     0.006   
WTCCC Bipolar disorder 
case 0.7946 0.0049 0.2794 0.0063 0.2791 0.0052 0.08 <0.0001 482969 0.8409 25 1998 
control 0.7950 0.0022 0.2786 0.0035 0.2787 0.0024    0.8404  3004 
p 8.7E-05  7.3E-08  ~0     ns   
dbGAP Bipolar disorder EA, phs000017 
case 0.7956 0.0087 0.2783 0.0052 0.2740 0.0028 0.14 <0.0001 845359 0.8644 47 1102 
control 0.7961 0.0073 0.2773 0.0043 0.2741 0.0023    0.8635  1081 
p 5.0E-10  ns  ~0     ns   
  
Table 2.  Distance to the MA set, heterozygosity, pairwise genetic distance (PGD), and correlation between MAC and case status.(Continued)   
dbGAP GAIN Schizophrenia EA, phs000021.v2.p1  
case 0.7988 0.0071 0.2732 0.0045 0.2705 0.0023 ns  858419 0.8254 50 1214 
control 0.7992 0.0071 0.2730 0.0040 0.2693 0.0125    0.8239  1442 
p ns  0.01  ~0     ns   
dbGAP nonGAIN Schizophrenia EA, phs000167.v1.p1 
case 0.7987 0.0074 0.2734 0.0059 0.2707 0.0038 0.07 0.007 861559 0.8235 52 1034 
control 0.7990 0.0077 0.2732 0.0047 0.2704 0.0028    0.8276  952 
p ns  ns  ~0     ns   
dbGAP Lung cancer H550/Ilmn, phs000336.v1.p1,   
case 0.7602 0.0019 0.32375 0.0023 0.3240 0.0017 0.14 <0.0001 542243 0.7767 84 776 
control 0.7605 0.0017 0.32376 0.0028 0.3242 0.0015    0.7747  845 
p 0.001  ns  ~0     ns   
dbGAP Lung cancer H610/Ilmn, phs000336.v1.p1 
case 0.7888 0.0331 0.2817 0.0493 0.3187 0.0024 0.12 <0.0001 571575 0.7888 90 3099 
control 0.7910 0.0330 0.2780 0.0507 0.3181 0.0026    0.7910  1925 
 3.7E-15  4.1E-08  ~0     8.0E-06   
dbGAP Breast cancer, phs000147.v1.p1 
case 0.7601 0.0046 0.32379 0.0032 0.3226 0.0020 0.044 <0.05 531623 0.7748 83 1069 
controal 0.7604 0.0042 0.32381 0.0027 0.3226 0.0018    0.7771  1083 
p ns  ns  ns     ns   
dbGAP Alcohol addiction, phs000092.v1.p1, EA cohort 
case 0.7859 0.0040 0.2888 0.0039 0.2889 0.0035 0.042 <0.05 959085 0.8708 189 1167 
control 0.7862 0.0037 0.2888 0.0037 0.2887 0.0031    0.8710  1366 
p ns  ns  ns     ns   
WTCCC T1D 
case 0.7947 0.0025 0.2669 0.0034 0.2787 0.0028 0.06 <0.0001 478370 0.8416 25 2000 
control 0.7949 0.0022 0.2789 0.0034 0.2788 0.0024    0.8402  3004 
p 0.022  ~0  ~0     ns   
WTCCC Rheumatoid arthritis 
case 0.7958 0.0024 0.2776 0.0089 0.2773 0.0105 0.036 0.01 481944 0.8516 27 1999 
control 0.7964 0.0022 0.2766 0.0035 0.2767 0.0024    0.8521  3004 
p 0.009  4.1E-07  ~0     ns   
WTCCC Inflammatory bowel disease or Crohn's disease 
case 0.7954 0.0135 0.2773 0.0118 0.2781 0.0144 0.085 <0.0001 483234 0.8463 26 2005 
control 0.7970 0.0022 0.2758 0.0035 0.2759 0.0024    0.8464  3004 
p 4.7E-07  7.4E-08  ~0     ns   
WTCCC Coronary artery disease 
case 0.79448 0.0024 0.2795 0.0052 0.2791 0.0026 ns  477416 0.8015 25 1988 
control 0.79447 0.0022 0.2792 0.0035 0.2793 0.0024    0.8002  3004 
p ns  0.007  ~0     ns   
WTCCC Hypertension 
case 0.7936 0.0014 0.2809 0.0049 0.2804 0.0015 ns  479524 0.8342 24 2001 
control 0.7935 0.0022 0.2806 0.0035 0.2807 0.0024    0.8336  3004 
p ns  0.03  ~0     ns   
 
a Shaded numbers indicate greater MA content or nucleotide diversity. Values represent ratio of the distance to the MA set (or het# or PGD) over the  
number of SNPs analyzed.  
b t test p value.  
c ~0 means p < 2.2E-16. 
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Methods for scoring the collective effect of SNPs: Minor alleles of common SNPs 
quantitatively affect traits/diseases and are under both positive and negative 
selection  
 
Supplementary Materials: 
 
Supplementary Figures: 
 
Supp. Figure S1.  Population distribution bell curve of MAC in various RIL panels.    
 
Supp.  Figure S2.   MAC value is independent of SNP numbers or random selection of SNPs.  A.  
The correlation curve between MAC of each BXD strain calculated from ~51K SNP and that from 1K 
SNP set 1 randomly selected from the ~51K SNP.  B.  The correlation curve between MAC of each 
BXD strain calculated from ~51K SNP and that from 1K SNP set 2 randomly selected from the ~51K 
SNP with no overlap with set 1.      
 
Supplementary Tables: 
Supp. Table S1.  MAC values of RIL strains or segregants 
 
Supp. Table S2.  Traits repeatedly linked (or not) with higher MAC.  aReproductive fitness includes 
uterus horn length (BXD), brood or litter size (CC mice and worm), and fetal weights in left horn of 
uterus (BXHHXB).  bAlcohol sensitivity was assayed by distance traveled after ethanol 
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injection.  cCancers include DEN induced liver tumors (BXD), urethane induced lung tumors with wild 
type kras2 (AXBBXA), and virus induced lymphomas (CXB).   
 
Supp. Table S3.  Correlation between traits and MAC values in BXD mice.  Significant associations 
are indicated by yellow color in column CW and CY. 
 
Supp. Table S4.  Significant correlations among selected traits linked with higher MAC in BXD 
mice.  Significance scores from Pearson correlation analysis with p <0.05, 0.01, and 0.001 represented 
by *, **, and ***, respectively.   
 
Supp. Table S5.  Multivariate regression analysis.   
 
 
Supp. Table S6.  MA correlation with yeast growth in the presence of a compound.  aFDA-
approved drugs in italics. 
 
Supp. Table S7.  Correlations between higher MAC and clinical traits.   
 
Extended experimental procedures: 
 
Naive inbred, specific pathogen-free (SPF status), 8- to 12-week-old BXD RIL animals as well as 
the parental C57BL/6J and DBA/2J were used for the study of immune response to S. aureus.  Animals 
were housed at Harlan (the Netherlands).  Mice were maintained under standard conditions and 
according to institutional guidelines. All experiments were approved by the appropriate ethical board 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany).  
Mice were inoculated with 4 x 107 cfu of S. aureus in 0.2 ml of PBS via a lateral tail vein.  For 
determination of bacterial loads (cfu), infected mice were sacrificed by CO2 asphyxiation at 48h post 
infection and the amount of bacteria determined by preparing liver homogenates in 5 ml of PBS and 
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plating 10-fold serial dilutions on blood agar. Bacteria colonies were counted after incubation for 24 
hours at 37°C.  
BXD animals were used for ectromelia virus infection.  90 pfu of ectromelia virus was injected 
into one rear footpad of mice while under anesthesia.  Animals were monitored daily for the formation 
of secondary dermal lesions over a two week period post infection. The presence of secondary lesions at 
any point over the 2 week period was scored as positive for the trait, the absence scored as negative for 
the trait.    
For high fat diet experiment in mice, a total of 152 males of the parental strains C57BL/6J (B6) 
and DBA/2J (D2), F1 offspring of the initial cross between B6 and D2 (B6D2F1), and 29 BXD RI 
strains (BXD 1, 2, 6, 8, 11, 14,15,16, 24a, 27, 31, 32, 33, 38, 39, 40, 42, 43, 51, 61, 62, 68, 69, 73, 75, 86, 
87, 90, 96) were used in this study (Four to five males of each of the parental, F1 and BXD strains were 
used).  Mice were purchased from The Jackson Laboratory and were bred in the facility of the Neuro-
Bsik consortium from the VU University Amsterdam, Netherlands.  At the age of four weeks, mice were 
shipped to the mouse facility of the Department for Crop and Animal Sciences, Faculty of Agriculture 
and Horticulture at Humboldt-Universitat zu Berlin, Germany.  Mice were maintained under 
conventional conditions and controlled lighting with a 12:12 hours light:dark cycle at a temperature of 
22 ± 2 °C and a relative humidity of 65%.  They were reared in groups of three to four individuals of the 
same sex in macrolon cages with a 350 cm2 floor space (E. Becker & Co (Ebeco) GmbH, Castrop-
Rauxel, Germany) and with bedding type S 80/150, dust-free (Rettenmeier Holding AG, Wilburgstetten, 
Germany).  All individuals had ad libitum access to food and water. 
Beginning at the age of 4 weeks, mice were fed a high-fat diet (HFD) (Ssniff® diet S8074-E010, 
Germany) until 20 weeks. The diet contained 20.7% crude protein, 25.1% crude fat, 5.0% crude fiber, 
5.9% crude ash, 39.7% N-free extract, 20.0% starch, 17.5% sugar, vitamins, trace elements, amino acids, 
and minerals (19.1 MJ/kg metabolizable energy; thereof 45% energy from fat, 31% from carbohydrates, 
and 24% from proteins). The fat in the diet derived from coconut oil and suet. 
Four to five males of each of the parental, F1 and BXD strains were used for Attenuated Total 
Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) measurements.  At 20 weeks, mice 
were fasted for two hours, anesthetized under isofluorane and decapitated using surgical scissors.  After 
exsanguinations, reproductive fat pads (which was the epididymal adipose tissue), liver, and quadriceps 
muscle (comprised of Musculus rectus femoris, Musculus vastus intermedius, Musculus vastus lateralis, 
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and Musculus vastus medialis) were dissected and weighed. All tissues were immediately frozen in 
liquid nitrogen and stored at -80 oC until ATR-FTIR studies.  
 
Phenotypes recorded: 
Total fat weight at 42 days on high fat diet (g, 45% energy from fat) measure by Magnetic resonance 
interference (MRI) 
Fat gain between 6 and 8 weeks on high fat diet (g, 45% energy from fat) 
Total lean weight at 42 days on high fat diet (g, 45% energy from fat) measure by Magnetic resonance 
interference (MRI) 
Lean gain between 6 and 8 weeks on high fat diet (g, 45% energy from fat) 
Body weight at 28 days on high fat diet (g, 45% energy from fat) 
Body weight gain between 5 and 6 weeks on high fat diet (g, 45% energy from fat) 
Body length from the nose until the tail at 42 days  
Serum glucose level at 70 days on high fat diet (g, 45% energy from fat) 
Food Intake at 7 weeks 
Food Intake between 7 and 10 weeks 
Brain weight at 140 days on high fat diet (g, 45% energy from fat) 
Weight of subcutaneous adipose tissue (upon the gluteal Mucsculus maximus between the legs, left and 
right of the tail) at 140 days on high fat diet (g, 45% energy from fat) 
Weight of brown adipose tissue (located on the back, along the upper half of the spine and toward the 
shoulders) at 140 days on high fat diet (g, 45% energy from fat) 
Serum level of leptin in males at 140 days on high fat diet (g, 45% energy from fat) 
Unsaturated fat content in reproductive adipose tissue in males at 140 days on high fat diet measure by 
Fourier Transform Infrared Spectroscopy (FTIR) 
 
Supplementary Acknowledgements: 
 
We wish to acknowledge all of the investigators and funding agencies that enabled the deposition of data 
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This study makes use data generated by the Wellcome Trust Case-Control Consortium.  A full list of the 
investigators who contributed to the generation of the data is available from www.wtccc.org.uk.  
Funding for the WTCCC project was provided by the Wellcome Trust under award 076113 and 085475. 
 
Funding support for the GWAS of Gene and Environment Initiatives in Type 2 Diabetes was provided 
through the NIH Genes, Environment and Health Initiative [GEI] (U01HG004399). The human subjects 
participating in the GWAS derive from The Nurses’ Health Study and Health Professionals’ Follow-up 
Study and these studies are supported by National Institutes of Health grants CA87969, CA55075, and 
DK58845. Assistance with phenotype harmonization and genotype cleaning, as well as with general 
study coordination, was provided by the Gene Environment Association Studies, GENEVA 
Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National 
Center for Biotechnology Information. Funding support for genotyping, which was performed at the 
Broad Institute of MIT and Harvard, was provided by the NIH GEI (U01HG004424). The datasets used 
for the analyses described in this manuscript were obtained from dbGaP at 
[http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000091.v1.p1] through 
dbGaP accession number [phs000091.v2.p1]. 
 
This work utilized in part data from the NINDS DbGaP database from the CIDR:NGRC  
PARKINSON’S DISEASE STUDY through dbGaP accession number phs000196.v2.p1. 
 
Funding support for NINDS Parkinsons Disease was provided by the National Institute for Neurological 
Disease and Stroke (NINDS) and the genotyping of samples was provided by the Singleton Lab (NIA 
Laboratory of Neurogenetics)with support from NINDS. The dataset(s) used for the analyses described 
in this manuscript were obtained from the NINDS Database found at http://view.ncbi.nlm.nih.gov/dbgap 
through dbGaP accession number phs000089.v3.p2. 
 
Funding support for the companion studies, Genome-Wide Association Study of Schizophrenia (GAIN) 
and Molecular Genetics of Schizophrenia - nonGAIN Sample (MGS_nonGAIN), was provided by 
Genomics Research Branch at NIMH see below) and the genotyping and analysis of samples was 
provided through the Genetic Association Information Network (GAIN) and under the MGS U01s: 
MH79469 and MH79470. Assistance with data cleaning was provided by the National Center for 
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Biotechnology Information. The MGS dataset(s) used for the analyses described in this manuscript were 
obtained from the database of Genotype and Phenotype (dbGaP) found at 
http://www.ncbi.nlm.nih.gov/gap through dbGaP accession numbers phs000021.v2.p1 (GAIN) and 
phs000167.v1.p1 (nonGAIN). Samples and associated phenotype data for the MGS GWAS study were 
collected under the following grants: NIMH Schizophrenia Genetics Initiative U01s: MH46276 (CR 
Cloninger), MH46289 (C Kaufmann), and MH46318 (MT Tsuang); and MGS Part 1 (MGS1) and Part 2 
(MGS2) R01s: MH67257 (NG Buccola), MH59588 (BJ Mowry), MH59571 (PV Gejman), MH59565 
(Robert Freedman), MH59587 (F Amin), MH60870 (WF Byerley), MH59566 (DW Black), MH59586 
(JM Silverman), MH61675 (DF Levinson), and MH60879 (CR Cloninger). Further details of collection 
sites, individuals, and institutions may be found in data supplement Table 1 of Sanders et al. (2008; 
PMID: 18198266) and at the study dbGaP pages.” 
 
Funding support for the GAIN Major Depression: Stage 1 Genome-wide Association In Population 
Based Samples Study (parent studies: Netherlands Study of Depression and Anxiety (NESDA) and the 
Netherlands Twin Register (NTR)) was provided by the Netherlands Scientific Organization (904-61-
090, 904-61-193, 480-04-004, 400-05-717, NWO Genomics, SPI 56-464- 1419) the Centre for 
Neurogenomics and Cognitive Research (CNCR-VU); the European Union (EU/WLRT-2001-01254), 
ZonMW (geestkracht program, 10-000-1002), NIMH (RO1 MH059160) and matching funds from 
participating institutes in NESDA and NTR, and the genotyping of samples was provided through the 
Genetic Association Information Network (GAIN). The dataset(s) used for the analyses described in this 
manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at 
http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000020.v2.p1.  Samples and 
associated phenotype data for the GAIN Major Depression: Stage 1 Genome-wide Association In 
Population Based Samples Study (PI: Dr. Patrick F. Sullivan, MD, University of North Carolina) were 
provided by Dr. Dorret I. Boomsma, PhD and Dr. Eco de Geus, PhD VU University Amsterdam (PIs 
NTR), Dr. Brenda W. Penninx, PhD, VU University Medical Center Amsterdam, Dr. Frans Zitman, MD 
PhD, Leiden University Medical Center, Leiden, and Dr. Willem Nolen, MD PhD, University Medical 
Center Groningen (PIs and site-PIs NESDA). 
 
Funding support for the Whole Genome Association Study of Bipolar Disorder was provided by the 
National Institute of Mental Health (NIMH) and the genotyping of samples was provided through the 
 7 
Genetic Association Information Network (GAIN). The datasets used for the analyses described in this 
manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at 
http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000017.v3.p1. Samples and 
associated phenotype data for the Collaborative Genomic Study of Bipolar Disorder were provided by 
the The NIMH Genetics Initiative for Bipolar Disorder. Data and biomaterials were collected in four 
projects that participated in NIMH Bipolar Disorder Genetics Initiative. From 1991-98, the Principal 
Investigators and Co-Investigators were: Indiana University, Indianapolis, IN, U01 MH46282, John 
Nurnberger, M.D., Ph.D., Marvin Miller, M.D., and Elizabeth Bowman, M.D.; Washington University, 
St. Louis, MO, U01 MH46280, Theodore Reich, M.D., Allison Goate, Ph.D., and John Rice, Ph.D.; 
Johns Hopkins University, Baltimore, MD U01 MH46274, J. Raymond DePaulo, Jr., M.D., Sylvia 
Simpson, M.D., MPH, and Colin Stine, Ph.D.; NIMH Intramural Research Program, Clinical 
Neurogenetics Branch, Bethesda, MD, Elliot Gershon, M.D., Diane Kazuba, B.A., and Elizabeth 
Maxwell, M.S.W. Data and biomaterials were collected as part of ten projects that participated in the 
NIMH Bipolar Disorder Genetics Initiative. From 1999-03, the Principal Investigators and Co-
Investigators were: Indiana University, Indianapolis, IN, R01 MH59545, John Nurnberger, M.D., Ph.D., 
Marvin J. Miller, M.D., Elizabeth S. Bowman, M.D., N. Leela Rau, M.D., P. Ryan Moe, M.D., Nalini 
Samavedy, M.D., Rif El-Mallakh, M.D. (at University of Louisville), Husseini Manji, M.D. (at Wayne 
State University), Debra A. Glitz, M.D. (at Wayne State University), Eric T. Meyer, M.S., Carrie Smiley, 
R.N., Tatiana Foroud, Ph.D., Leah Flury, M.S., Danielle M. Dick, Ph.D., Howard Edenberg, Ph.D.; 
Washington University, St. Louis, MO, R01 MH059534, John Rice, Ph.D, Theodore Reich, M.D., 
Allison Goate, Ph.D., Laura Bierut, M.D. ; Johns Hopkins University, Baltimore, MD, R01 MH59533, 
Melvin McInnis M.D. , J. Raymond DePaulo, Jr., M.D., Dean F. MacKinnon, M.D., Francis M. 
Mondimore, M.D., James B. Potash, M.D., Peter P. Zandi, Ph.D, Dimitrios Avramopoulos, and Jennifer 
Payne; University of Pennsylvania, PA, R01 MH59553, Wade Berrettini M.D.,Ph.D. ; University of 
California at Irvine, CA, R01 MH60068, William Byerley M.D., and Mark Vawter M.D. ; University of 
Iowa, IA, R01 MH059548, William Coryell M.D. , and Raymond Crowe M.D. ; University of Chicago, 
IL, R01 MH59535, Elliot Gershon, M.D., Judith Badner Ph.D. , Francis McMahon M.D. , Chunyu Liu 
Ph.D., Alan Sanders M.D., Maria Caserta, Steven Dinwiddie M.D., Tu Nguyen, Donna Harakal; 
University of California at San Diego, CA, R01 MH59567, John Kelsoe, M.D., Rebecca McKinney, 
B.A.; Rush University, IL, R01 MH059556, William Scheftner M.D. , Howard M. Kravitz, D.O., 
M.P.H., Diana Marta, B.S., Annette Vaughn-Brown, MSN, RN, and Laurie Bederow, MA; NIMH 
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Intramural Research Program, Bethesda, MD, 1Z01MH002810-01, Francis J. McMahon, M.D., Layla 
Kassem, PsyD, Sevilla Detera-Wadleigh, Ph.D, Lisa Austin,Ph.D, Dennis L. Murphy, M.D. 
 
Funding support for the GWAS of Lung Cancer and Smoking was provided through the NIH Genes, 
Environment and Health Initiative [GEI] (Z01 CP 010200). The human subjects participating in the 
GWAS derive from The Environment and Genetics in Lung Cancer Etiology (EAGLE) case-control 
study and the Prostate, Lung Colon and Ovary Screening Trial and these studies are supported by 
intramural resources of the National Cancer Institute. Assistance with phenotype harmonization and 
genotype cleaning, as well as with general study coordination, was provided by the Gene Environment 
Association Studies, GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning 
was provided by the National Center for Biotechnology Information. Funding support for genotyping, 
which was performed at the Johns Hopkins University Center for Inherited Disease Research, was 
provided by the NIH GEI (U01HG004438). The datasets used for the analyses described in this 
manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession 
number phs000336. 
 
The CGEMS Breast Cancer study was supported by the National Cancer Institute. Details of the study 
can be found at http://cgems.cancer.gov/data and in reference 28. The data was obtained from dbGaP 
under accession phs000147v1. 
 
Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through 
the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the 
genome-wide association studies funded as part of the Gene Environment Association Studies 
(GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as 
with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). 
Assistance with data cleaning was provided by the National Center for Biotechnology Information. 
Support for collection of datasets and samples was provided by the Collaborative Study on the Genetics 
of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence 
(COGEND; P01 CA089392), and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). 
Funding support for genotyping, which was performed at the Johns Hopkins University Center for 
Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on 
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Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the NIH contract "High 
throughput genotyping for studying the genetic contributions to human disease" 
(HHSN268200782096C). The datasets used for the analyses described in this manuscript were obtained 
from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi- bin/study.cgi?study_id=phs000092.v1.p1 
through dbGaP accession number phs000092.v1.p1. 
 
 
Supplementary Figure S1.  MAC distribution profiles among the strains in a RILs or segregants panel
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Supplementary Table S2.  Selected traits consistently linked (or not) with higher MAC in different panels of RILs          
    Reprod. fit.a   Life span   Alcohol sens.b   Cancerc   Blood pressure. 
RIL panel  Correlation r p #   r p #   r p #   r p #   r p # 
BXD 
Pearson -0.23 ns 61   -0.12 ns 20   -0.27 0.04 25   0.22 ns 22   -0.27 ns 21 
Spearman -0.25 0.05     -0.16 ns     -0.25 0.05     0.13 ns     -0.28 ns   
                                          
AXBBXA 
Pearson                         t test, p<0.05 17         
Spearman                         Lung tumor           
                                          
CXB 
Pearson                         0.69 ns 7         
Spearman                         0.82 0.03           
                                          
LXS 
Pearson         -0.25 ns 43   -0.23 0.05 74                
Spearman         -0.29 0.06     -0.27 0.02                  
                                         
CC (F6) 
Pearson -0.14 0.04 245                                
Spearman -0.13 ns                                  
                                         
BXHHXB 
Pearson -0.49 0.02 24                          -0.02 ns 32 
Spearman -0.50 0.01                            -0.06 ns   
                                         
Worm Pearson -0.45 0.002 42                                
Kruglyak Spearman -0.45 0.002                                  
                                         
Worm Pearson         -0.27 ns 35                        
Kammenga Spearman         -0.35 0.04                          
aReproductive fitness includes uterus horn length (BXD), litter/brood size (CC, Worm), and fetal weights in left horn of uterus (BXHHXB rat).    
bAlcohol sensitity was assayed by distance traveled after ethanol injection.                        
cCancer includes DEN induced liver tumor (BXD), urethane induced lung tumor (AXBBXA), and virus induced lymphoma (CXB).         
 
Supplementary Table S4.  Correlations among selected traits linked with higher MAC in BXD mice                                 
  Sample Pearson                                                        
GN IDa # r p Trait  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  Trait description 
10145 25 -0.63 0.001 1            **   *b                     * Maxi-threshold to ethanol induced ataxia 
10169 25 -0.63 0.001 2      * *       *                       Methamphet. induced temp. change 
11453 61 -0.42 0.001 3                *   * ***         **       Blood ethanol concentration for males 
11307 60 -0.41 0.001 4          **               ** * *         Hargreaves' test for males    
11672 57 -0.42 0.001 5                              *       * Open field rearing activity from 10-15 min 
10022 20 0.60 0.006 6              **   **               **     Saccharin preference versus water ratio 
10493 25 -0.47 0.017 7                  *                     Cocaine induced difference in locomotion 
10301 23 0.53 0.010 8                              *     *   Cocaine, nose pokes in hole board  
10494 24 -0.51 0.012 9                                *       Ethanol induced difference in locomotion 
10917 15 -0.68 0.006 10                        **               Anxiety, transitions between light and dark  
14220 28 0.51 0.005 11                          *     **   *   Resistin level after high fat diet   
12540 22 -0.69 0.0004 12                                        Transferrin saturation fed 3 ppm iron diet 
11725 57 0.50 0.007 13                                      * Gain in weight between 8 and 9 wks 
12886 16 0.64 0.008 14                              *         Oxygen consumption males   
12568 38 0.57 0.0001 15                                    **   Deoxycorticosterone in cerebral cortex 
12852 16 0.68 0.004 16                                    *   Food intake of 13-week old females 
12554 24 0.38 0.070 17                                        Depression assay, duration of immobility 
14226 28 -0.45 0.017 18                                        IL17 level after high fat diet   
12396 64 0.28 0.026 19                                        Time in open quadr. in elevated 0 maze 
aGeneNetwork identification number.                                                               
bSymbols *, **, and *** represent p < 0.05, 0.01, 0.001 respectively, from Pearson analysis.                                 
       
    
                      
 
Supplementary Table S6. MAC correlation with yeast growth in the presence of 
a compound using 105 segregants. 
 
   Pearson  Spearman 
Compounds  r p  r p 
diphenyleneiodonium 64 h 16 µM -0.44 <0.0001  -0.39 <0.0001 
sertraline 68 h 20.9 µMa  -0.36 0.0004  -0.36 0.0003 
sertraline 52 h 20.9 µM  -0.30 0.003  -0.30 0.004 
sertraline 78 h 20.9 µM  -0.31 0.002  -0.33 0.001 
diphenyleneiodonium 64 h 16 µM -0.30 0.003  -0.29 0.004 
alverine 118 h 105.5 µM  -0.29 0.004  -0.31 0.002 
tamoxifen 70 h 13.5 µM   -0.33 0.001  -0.28 0.007 
trimeprazine 80 h 83.8 µM -0.33 0.001  -0.33 0.001 
chlorpromazine 70 h 15.7 µM -0.31 0.003  -0.27 0.009 
sertraline 90 h 20.9 µM  -0.31 0.002  -0.32 0.002 
cinnarazine 68 h 33.9 µM -0.27 0.009  -0.22 0.03 
trifluoperazine 90 h 26 µM -0.27 0.007  -0.27 0.007 
aFDA-approved drugs in italics.       
 
Supplementary Table S7. Correlations between MAC and clinical traits.   
 
 Pearson Spearman 
 r p r p 
Alcohol addiction cases (1167 sub.  Ave. 
age 38.1 yr) 
    
Cocaine dependence 0.11 0.0002 0.08 0.008 
Cocaine_sx1 (tolerance) 0.09 0.001 0.06 0.04 
Cocaine_sx2 (withdrawal) 0.09 0.002 0.07 0.02 
Cocaine_sx3 (more than intended) 0.09 0.002 0.07 0.01 
Cocaine_sx4 (desire to cut) 0.11 0.0003 0.07 0.02 
Cocaine_sx5 (time spent to use) 0.11 0.0002 0.08 0.005 
Cocaine_sx6 (reduced social act.) 0.08 0.009 0.07 0.03 
Sex (female 2, male 1) -0.13 < 0.0001 -0.11 0.0001 
Trauma sexual -0.09 0.004 -0.07 0.04 
Education level  -0.08 0.004 -0.06 0.03 
Cigarette daily -0.08 -0.003 0.06 0.06 
Alcohol addiction controls (1366 sub.  Ave. 
age 38.6 yr) 
    
Education level  -0.12 < 0.0001 -0.05 0.08 
Income -0.13 < 0.0001 -0.09 0.002 
Height -0.12 < 0.0001 -0.09 0.002 
Nic_sx3 (use more than intended) -0.07 0.02 -0.05 0.05 
Alc_sx3 (use more than intended) -0.10 0.0001 -0.09 0.0005 
Cigarette daily -0.05 0.05 -0.05 0.07 
PD controls (ave. age 72.8 yr)     
Life span cohort 1 (46 sub, ave. age 88.2 yr) -0.30 <0.05 ns  
Life span cohort 2 (34 sub, ave. age 87.2 yr) ns  -0.40 <0.05 
NSAIDs OTC load, cohort 1 (999 sub.) 0.08 0.1 (ns) ns  
NSAIDs OTC load, cohort 2 (993 sub.) 0.14 0.003 ns  
     
 
